000 02379nam a22004935i 4500
001 978-3-642-24980-8
003 DE-He213
005 20140220083304.0
007 cr nn 008mamaa
008 120102s2012 gw | s |||| 0|eng d
020 _a9783642249808
_9978-3-642-24980-8
024 7 _a10.1007/978-3-642-24980-8
_2doi
050 4 _aQR46
072 7 _aMMFM
_2bicssc
072 7 _aMED052000
_2bisacsh
082 0 4 _a616.9041
_223
100 1 _aKotb, Essam.
_eauthor.
245 1 0 _aFibrinolytic Bacterial Enzymes with Thrombolytic Activity
_h[electronic resource] /
_cby Essam Kotb.
264 1 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg,
_c2012.
300 _aXII, 74p. 15 illus., 6 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aSpringerBriefs in Microbiology
520 _aStress, high blood pressure, smoking, pollution, fast foods, overweight, excessive travelling, surgery, less movement are common features in our modern life. These features are risky for blood clotting disorders. According to WHO, over 29% of the total mortalities worldwide are due to thrombosis. By the year, 2020 cardiovascular diseases (CVDs) may cause an estimated 25 million deaths per year, thus antithrombotic therapy is of great interest. The available thrombolytic agents such as urokinase are highly expensive, antigenic, quite unspecific, pyretogenic and hemorrhagenic. Therefore, the production of fibrinolysing enzymes, which rapidly dissolute thrombi within the vascular tree, without the detriments by microorganisms, as described in this book, is the desirable aim of today’s research.
650 0 _aMedicine.
650 0 _aHuman physiology.
650 0 _aMicrobiology.
650 0 _aCardiology.
650 0 _aHematology.
650 1 4 _aBiomedicine.
650 2 4 _aMedical Microbiology.
650 2 4 _aHematology.
650 2 4 _aCardiology.
650 2 4 _aHuman Physiology.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783642249792
830 0 _aSpringerBriefs in Microbiology
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-642-24980-8
912 _aZDB-2-SBL
999 _c102365
_d102365